Filtered By:
Procedure: Hemodialysis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 19534 results found since Jan 2013.
Immobilization of heparin-mimetic biomacromolecules on Fe3O4 nanoparticles as magnetic anticoagulant via mussel-inspired coating
Publication date: April 2020Source: Materials Science and Engineering: C, Volume 109Author(s): Chenxi Li, Man Zhang, Xiaoling Liu, Weifeng Zhao, Changsheng ZhaoAbstractHere, we report the application of mussel-inspired surface coating to prepare heparin-mimetic biomacromolecules modified magnetic Fe3O4 nanoparticles as recyclable anticoagulant. Sodium alginate sulfate (SAS), which has the similar chemical structure and bioactivity with heparin, was synthesized at first. Dopamine (DA) was then grafted onto the backbone of SAS as the mussel-inspired adhesive macromolecule (DA-g-SAS), followed by being coated onto Fe3O4 nanop...
Source: Materials Science and Engineering: C - December 12, 2019 Category: Materials Science Source Type: research
Highly adsorptive oxidized starch nanoparticles for efficient urea removal
This study aims to develop a nano-adsorbent, derived from corn starch for urea removal. Oxidized starch nanoparticles (oxy-SNPs) were prepared via liquid phase oxidation, followed by chemical dissolution and non-solvent precipitation. The oxy-SNPs possessed Z-average size of 177.7 nm with carbonyl and carboxyl contents of 0.068 and 0.048 per 100 glucose units, respectively. The urea adsorption achieved the equilibrium after 4 h with 95% removal. The adsorption mechanism fitted Langmuir isotherm while the adsorption kinetics obeyed pseudo-second-order model. This new material has a maximum adsorption capacity of 185.2...
Source: Carbohydrate Polymers - August 18, 2018 Category: Biomedical Science Source Type: research
In search for a biochemical marker of overhydration in hemodialysis: the "magic bullet" yet to be found.
Authors: Stompór T, Winiarska A
PMID: 26266684 [PubMed - in process]
Source: Polskie Archiwum Medycyny Wewnetrznej - August 15, 2015 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research
Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis
CONCLUSIONS: Currently, there is no available high certainty evidence to support one treatment over another for CRBSIs. The benefit of using ethanol lock treatment in combination with systemic antibiotics compared to systemic antibiotics alone for CRBSIs in patients receiving maintenance HD remains uncertain due to the very low certainty of the evidence. Hence, further RCTs to identify the benefits and harms of CRBSI treatment options are needed. Future studies should unify CRBSI and cure definitions and improve methodological design.PMID:35363884 | PMC:PMC8974891 | DOI:10.1002/14651858.CD013554.pub2
Source: Cochrane Database of Systematic Reviews - April 1, 2022 Category: General Medicine Authors: Beatriz M Almeida Daniel H Moreno Vladimir Vasconcelos Daniel G Cacione Source Type: research
Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
CONCLUSIONS: Given the low-certainty evidence, we are uncertain whether intermittent locking with heparin results in fewer central venous catheter occlusions than intermittent locking with normal saline in adults. Low-certainty evidence suggests that heparin may have little or no effect on catheter patency duration. Although we found no evidence of differences in safety (CVC-related bloodstream infections, mortality, or haemorrhage), the combined studies were not powered to detect rare adverse events such as heparin-induced thrombocytopaenia. Further research conducted over longer periods would reduce the current uncertain...
Source: Cochrane Database of Systematic Reviews - July 18, 2022 Category: General Medicine Authors: Eduardo L ópez-Briz Vicente Ruiz Garcia Juan B Cabello Sylvia Bort-Mart í Rafael Carbonell Sanchis Source Type: research
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
CONCLUSIONS: Tenapanor is the first drug in its class that lowers hyperphosphatemia in ESKD patients through a novel mechanism of action involving paracellular inactive transport. Although more studies are needed, early results indicate that tenapanor may have a place in managing hyperphosphatemia in ESKD patients both as monotherapy and as an adjunct to existing phosphate binder therapy.PMID:35041802 | DOI:10.18433/jpps32284
Source: J Pharm Pharm Sci - January 18, 2022 Category: Drugs & Pharmacology Authors: Tiffany Lin Akram Al-Makki Brian Shepler Source Type: research
